{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Serosal', 'Definition: A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who', 'Effusions', 'demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias,', '(cont.)', 'medications, or poisoning. It can lead to generalized edema and multiple organ failure.', 'Edema', 'Edema face', 'Localized facial edema', 'Moderate localized facial', 'Severe swelling; limiting', '-', 'edema; limiting instrumental', 'self-care ADL', 'ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.', 'Edema limbs', '5 - 10% inter-limb', '> 10 - 30% inter-limb', '> 30% inter-limb', '-', 'discrepancy in volume or', 'discrepancy in volume or', 'discrepancy in volume;', 'circumference at point of', 'circumference at point of', 'gross deviation from', 'greatest visible', 'greatest visible difference;', 'normal anatomic', 'difference; swelling or', 'readily apparent obscuration', 'contour; limiting self-', 'obscuration of anatomic', 'of anatomic architecture;', 'care ADL', 'architecture on close', 'obliteration of skin folds;', 'inspection', 'readily apparent deviation', 'from normal anatomic', 'contour; limiting', 'instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.', 'Edema trunk', 'Swelling or obscuration', 'Readily apparent', 'Gross deviation from', 'of anatomic architecture', 'obscuration of anatomic', 'normal anatomic', 'on close inspection', 'architecture; obliteration of', 'contour; limiting self-', 'skin folds; readily apparent', 'care ADL', 'deviation from normal', 'anatomic contour; limiting', 'instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.', '138']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Edema', 'Localized edema', 'Localized to dependent', 'Moderate localized edema', 'Severe localized edema', '-', '(cont.)', 'areas, no disability or', 'and intervention indicated;', 'and intervention', 'functional impairment', 'limiting instrumental ADL', 'indicated; limiting self-', 'care ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.', 'Periorbital edema', 'Soft or non-pitting', 'Indurated or pitting edema;', 'Edema associated with', 'topical intervention', 'visual disturbance;', 'indicated', 'increased intraocular', 'pressure, glaucoma or', 'retinal hemorrhage; optic', 'neuritis; diuretics', 'indicated; operative', 'intervention indicated', 'Definition: A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.', 'Labs', 'Hypo-albuminemia', '< LLN - 3 g/dL;', '<3-2g/dL; <30-20 g/L', '<2 g/dL; < 20 g/L', 'Life-threatening', '< LLN - 30 g/L', 'consequences; urgent', 'intervention indicated', 'Definition: A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.', 'Neutrophil count decreased < LLN - 1500/mm\u00b3;', '< 1500 - 1000/mm\u00b3;', '< 1000 - 500/mm\u00b3:', '< 500/mm\u00b3; <0.5 x 109/L', '< LLN - 1.5 X 109/L', '< 1.5 - 1.0 X 109/L', '< 1.0 - 0.5 X 109/L', 'Definition: A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.', 'Platelet count decreased', '< LLN - 75,000/mm\u00b3;', '< 75,000 - 50,000/mm\u00b3;', '< 50,000 - 25,000/mm\u00b3;', '< 25,000/mm\u00b3;', '< LLN - 75.0 X 109/L', '< 75.0-50.0 x 109/L -', '< 50.0 - 25.0 x 10%/L -', '< 25.0 X 109/L', 'Definition: A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.', '139']\n\n###\n\n", "completion": "END"}